U.S. markets closed
  • S&P Futures

    3,845.00
    +35.75 (+0.94%)
     
  • Dow Futures

    31,154.00
    +242.00 (+0.78%)
     
  • Nasdaq Futures

    13,064.00
    +153.00 (+1.19%)
     
  • Russell 2000 Futures

    2,238.10
    +38.90 (+1.77%)
     
  • Crude Oil

    62.65
    +1.15 (+1.87%)
     
  • Gold

    1,743.70
    +14.90 (+0.86%)
     
  • Silver

    26.94
    +0.50 (+1.91%)
     
  • EUR/USD

    1.2090
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • Vix

    27.95
    -0.94 (-3.25%)
     
  • GBP/USD

    1.3989
    +0.0066 (+0.48%)
     
  • USD/JPY

    106.6670
    +0.1650 (+0.15%)
     
  • BTC-USD

    46,411.54
    -184.62 (-0.40%)
     
  • CMC Crypto 200

    928.07
    -5.07 (-0.54%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    29,641.56
    +675.55 (+2.33%)
     

Ultragenyx: 4Q Earnings Snapshot

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported a loss of $24 million in its fourth quarter.

The Novato, California-based company said it had a loss of 37 cents per share. Losses, adjusted for non-recurring gains, were $1.34 per share.

The results missed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $1.06 per share.

The biotechnology company posted revenue of $91.5 million in the period, beating Street forecasts. Seven analysts surveyed by Zacks expected $71.2 million.

For the year, the company reported that its loss narrowed to $186.6 million, or $3.07 per share. Revenue was reported as $271 million.

Ultragenyx shares have climbed 18% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $162.78, more than doubling in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE